These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 9456668

  • 1. Fluconazole resistant oral candidiasis in HIV-infected patients.
    Tumbarello M, Tacconelli E, Caldarola G, Morace G, Cauda R, Ortona L.
    Oral Dis; 1997 May; 3 Suppl 1():S110-2. PubMed ID: 9456668
    [Abstract] [Full Text] [Related]

  • 2. Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection.
    Tumbarello M, Caldarola G, Tacconelli E, Morace G, Posteraro B, Cauda R, Ortona L.
    J Antimicrob Chemother; 1996 Oct; 38(4):691-9. PubMed ID: 8937963
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients.
    Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE.
    J Infect Dis; 1996 Jan; 173(1):219-25. PubMed ID: 8537662
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Fluconazole-resistant Candida species from HIV infected patients with recurrent Candida stomatitis: cross resistance to itraconazole and ketoconazole].
    Metzger S, Hofmann H.
    Mycoses; 1997 Jan; 40 Suppl 1():56-63. PubMed ID: 9417515
    [Abstract] [Full Text] [Related]

  • 7. Relative growth measurement of Candida species in a single concentration of fluconazole predicts the clinical response to fluconazole in HIV infected patients with oral candidosis.
    Cartledge JD, Midgley J, Gazzard BG.
    J Antimicrob Chemother; 1996 Feb; 37(2):275-83. PubMed ID: 8707737
    [Abstract] [Full Text] [Related]

  • 8. The prevalence, risk factors and antifungal sensitivity pattern of oral candidiasis in HIV/AIDS patients in Kumba District Hospital, South West Region, Cameroon.
    Ambe NF, Longdoh NA, Tebid P, Bobga TP, Nkfusai CN, Ngwa SB, Nsai FS, Cumber SN.
    Pan Afr Med J; 2020 Feb; 36():23. PubMed ID: 32774600
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of fluconazole and itraconazole in the treatment of oral candidiasis in HIV patients.
    Menon T, Umamaheswari K, Kumarasamy N, Solomon S, Thyagarajan SP.
    Acta Trop; 2001 Oct 22; 80(2):151-4. PubMed ID: 11600094
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in persons with HIV infection. Adult AIDS Clinical Trials Group Study Team 295.
    Fichtenbaum CJ, Zackin R, Rajicic N, Powderly WG, Wheat LJ, Zingman BS.
    AIDS; 2000 May 05; 14(7):845-52. PubMed ID: 10839593
    [Abstract] [Full Text] [Related]

  • 13. Determinants for the development of oropharyngeal colonization or infection by fluconazole-resistant Candida strains in HIV-infected patients.
    Masiá Canuto M, Gutiérrez Rodero F, Ortiz de la Tabla Ducasse V, Hernández Aguado I, Martín González C, Sánchez Sevillano A, Martín Hidalgo A.
    Eur J Clin Microbiol Infect Dis; 2000 Aug 05; 19(8):593-601. PubMed ID: 11014621
    [Abstract] [Full Text] [Related]

  • 14. Oral Candida isolates among HIV-infected subjects in Nigeria.
    Nweze EI, Ogbonnaya UL.
    J Microbiol Immunol Infect; 2011 Jun 05; 44(3):172-7. PubMed ID: 21524610
    [Abstract] [Full Text] [Related]

  • 15. Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients.
    Quereda C, Polanco AM, Giner C, Sánchez-Sousa A, Pereira E, Navas E, Fortún J, Guerrero A, Baquero F.
    Eur J Clin Microbiol Infect Dis; 1996 Jan 05; 15(1):30-7. PubMed ID: 8641300
    [Abstract] [Full Text] [Related]

  • 16. Post-antifungal effect of polyene, azole and DNA-analogue agents against oral Candida albicans and Candida tropicalis isolates in HIV disease.
    Anil S, Ellepola AN, Samaranayake LP.
    J Oral Pathol Med; 2001 Sep 05; 30(8):481-8. PubMed ID: 11545239
    [Abstract] [Full Text] [Related]

  • 17. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40.
    Goldman M, Cloud GA, Wade KD, Reboli AC, Fichtenbaum CJ, Hafner R, Sobel JD, Powderly WG, Patterson TF, Wheat LJ, Stein DK, Dismukes WE, Filler SG, AIDS Clinical Trials Group Study Team 323, Mycoses Study Group Study Team 40.
    Clin Infect Dis; 2005 Nov 15; 41(10):1473-80. PubMed ID: 16231260
    [Abstract] [Full Text] [Related]

  • 18. Relationship between fluconazole dosage regimens and the emergence of fluconazole-resistant Candida albicans.
    Goetz MB.
    AIDS; 1996 Mar 15; 10(3):335-6. PubMed ID: 8882674
    [No Abstract] [Full Text] [Related]

  • 19. Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients.
    Saag MS, Fessel WJ, Kaufman CA, Merrill KW, Ward DJ, Moskovitz BL, Thomas C, Oleka N, Guarnieri JA, Lee J, Brenner-Gati L, Klausner M.
    AIDS Res Hum Retroviruses; 1999 Nov 01; 15(16):1413-7. PubMed ID: 10555103
    [Abstract] [Full Text] [Related]

  • 20. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS.
    Newman SL, Flanigan TP, Fisher A, Rinaldi MG, Stein M, Vigilante K.
    Clin Infect Dis; 1994 Oct 01; 19(4):684-6. PubMed ID: 7803632
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.